Both progesterone and the insulin-like growth factors (IGFs) are critically involved in mammary gland development and also in breast cancer progression. However, how the progesterone and IGF signaling pathways interact with each other to regulate breast cancer cell growth remains unresolved. In this study, we investigated progesterone regulation of IGF signaling components in breast cancer cells. We found that insulin receptor substrate-2 (IRS-2) levels were markedly induced by progesterone and the synthetic progestin R5020 in MCF-7 and other progesterone receptor (PR) positive breast cancer cell lines, whereas IRS-1 and the IGF-I receptor were not induced. The antiprogestin RU486 blocked the R5020 effect on IRS-2 expression. Ectopic expression of either PR-A or PR-B in C4-12 breast cancer cells (estrogen receptor and PR negative) showed that progestin upregulation of IRS-2 was mediated specifically by PR-B. The IRS-2 induction by R5020 occurred via an increase of IRS-2 mRNA levels. Furthermore, progestin treatment prior to IGF-I stimulation resulted in higher tyrosine-phosphorylated IRS-2 levels, increased binding of IRS-2 to Grb-2 and the PI3K regulatory subunit p85, and correspondingly enhanced ERK and Akt activation, as compared with IGF-I-only conditions. Taken together, our data suggest that IRS-2 may play an important role in crosstalk between progesterone and the IGFs in breast cancer cells.
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Progesterone is proliferative in the normal mammary gland (Graham and Clarke, 1997) , but its inhibition of breast cancer cell growth in tissue culture has been well documented (Musgrove et al., 1991; Groshong et al., 1997; Lin et al., 1999) . Interestingly, progestins have been found to exert a biphasic regulation of breast cancer cell growth -accelerating cells through the first mitotic cell cycle and then arresting them in G1 of the second cycle. At this stage, the cell-cycle progression machinery is poised to restart, as expression of epidermal growth factor and its receptor is increased by progestins (Musgrove et al., 1991; Groshong et al., 1997) . Hence, it is proposed that progestins are inherently neither growth proliferative nor growth inhibitory, but rather sensitize breast cancer cells for growth factor and cytokine signals (Lange et al., 1998) .
The insulin-like growth factors (IGFs) are key regulators of cell proliferation, survival, and differentiation (LeRoith, 1996) . They play an important role in malignant transformation and invasion (Baserga, 1995) . Numerous lines of evidence support a role for the IGFs in breast cancer pathogenesis (Lee and Yee, 1995) . The IGF-I receptor (IGF-IR), upon activation by the IGFs, phosphorylates the insulin receptor substrates IRS-1 and IRS-2, which are multisite docking proteins that link multiple downstream signaling pathways by binding to a variety of SH2 domain-containing proteins (Yenush and White, 1997) . IRSs are also involved in signaling of insulin, interleukins, interferons, and growth hormone, and are implicated in breast cancer growth (Surmacz and Burgaud, 1995; Rocha et al., 1997; Chang et al., 2002) . The IRS network of upstream and downstream signaling may place them in a central position to coordinate multiple signaling pathways. IRS-1 and IRS-2, despite their structural and functional similarities, are not completely interchangeable (Bruning et al., 1997) .
Recently, much study has been directed to crosstalk between the IGFs and the estrogen receptor (ER) signaling in breast cancer cells (Dupont and Le Roith, 2001) , and IRS-1, IRS-2, and IGF-IR have been shown to be induced by estrogen (Lee et al., 1999) . However, how the IGFs interact with progesterone in breast cancer is less well defined. In an attempt to elucidate crosstalk and synergism between progesterone and IGF signaling in breast cancer cells, we have now investigated progesterone regulation of the IGF signaling pathway.
As a first step, we treated ER and PR positive (ER þ / PR þ ) MCF-7 cells in serum-free medium with the synthetic progestin R5020, and then tested how expression of IRS-1, IRS-2, and IGF-IR was affected. Immunoblot analysis of total cell lysates demonstrated that a single dose of 10 À8 m R5020 for 24 h remarkably increased IRS-2 levels in MCF-7 cells, while it did not alter the expression of IRS-1 and IGF-IR ( Figure 1a ). This is in contrast to the effect of estradiol, which upregulates all these proteins. The R5020 effect on IRS-2 was also observed in other ER þ /PR þ breast cancer cell lines like T47D and ZR75 (Figure 1b ). Similar but slightly weaker induction of IRS-2 also occurred with a single dose of 10 À8 m progesterone (Figure 1c ), probably due to progesterone's much shorter half-life in cell culture than R5020 (Groshong et al., 1997) . Moreover, the antiprogestin RU486 blocked the IRS-2 upregulation by R5020 in MCF-7 cells (Figure 1c ), suggesting that, as expected, the IRS-2 induction by progestins is mediated by PR in breast cancer cells.
To better define the role of progesterone and the two PR isoforms on IRS-2 in breast cancer cells, we established the expression of either PR isoform by stably transfecting PR-A or PR-B cDNA into C4-12 cells, a specifically selected MCF-7 cell subline that does not have detectable ER or PR (Oesterreich et al., 2001) . In PR-B-transfected C4-12 cells, IRS-2, but not IRS-1 or IGF-IR, was upregulated significantly by R5020 (Figure 2a ), while PR-B by itself had no ligandindependent induction of IRS-2 expression. In addition, the antiprogestin RU486 completely blocked the IRS-2 upregulation by R5020 in the C4-12/PR-B cells. As expected, the R5020 effect on IRS-2 was not observed in parental or vector-transfected C4-12 cells. The R5020- Figure 1 Progesterone induces IRS-2 expression in breast cancer cells. (a) MCF-7 cells were grown as described previously (Lee et al., 1999) . Cells were first starved for 16 h in serum-free medium (SFM), and then treated for 24 h with 10 À9 m estradiol or 10 À8 m R5020. Cell lysate proteins (40 mg) were separated by 8% SDS-PAGE and immunoblotted with antibodies against IRS-1 (Upstate, Lake Placid, NY, USA), IRS-2 (Upstate, Lake Placid, NY, USA), and IGF-IR (Santa Cruz Biotechnology, Santa Cruz, CA, USA). b-actin was used as a loading control. (b) T47D and ZR75 breast cancer cells were also treated as in (a) and subjected to Western blot analysis of IRS-1, IRS-2, and IGF-IR. (c) MCF-7 cells were treated for 24 h with 10 À8 m progesterone, 10 À8 m R5020, or 10 À8 m R5020 plus 10 À6 m RU486. Cell lysates were subjected to Western blot analysis of IRS-1 and IRS-2 (Figure 2a) , which re-emphasizes the fact that the two PR isoforms possess distinct gene transcriptional activities and that PR-B is transcriptionally more active (Richer et al., 2002) . Thus, our data suggest that it is PR-B that mediates the progestin effect on IRS-2 upregulation. The induction of IRS-2 by R5020 over the untreated control was noticeably stronger in C4-12/ PR-B cells than in MCF-7 cells (see Figure 1) , perhaps due to the finding that C4-12/PR-B cells have 3-5-fold higher PR-B protein levels than MCF-7 cells. Another explanation may be that the PR-A also present in MCF-7 cells might act as a repressor of PR-B in regulating IRS-2 expression (Vegeto et al., 1993) .
To extend the study of progesterone regulation of IRS-2 in C4-12/PR-B cells, we performed a dose response assay using a 24 h stimulation. As shown in Figure 2b , R5020 at concentrations as low as 10 À11 m dramatically increased IRS-2 levels. Maximal induction of IRS-2 expression occurred at 10 À9 m R5020 and higher. In a time course experiment using 10 À8 m R5020, we found that elevated IRS-2 protein levels were visible after 6 h of R5020 treatment and continued to increase throughout the 48 h time period (Figure 2c ). Similar dose response and time course results were also observed in MCF-7 cells (Figure 2b and c) . Taken together, these data suggest that the induction of IRS-2 is very sensitive to progesterone in PR-B-expressing breast cancer cells.
To assess whether progesterone uses transcriptional mechanisms to modulate IRS-2 levels, we first examined changes of IRS-2 mRNA concentrations in MCF-7 cells treated with R5020. RT-PCR analysis demonstrated that 10 À8 m R5020 treatment for 3 h significantly increased IRS-2 mRNA levels, while RU486 impaired this IRS-2 mRNA induction by R5020 (Figure 3a) . In the earlier time course experiment, IRS-2 protein was barely upregulated by R5020 by the 3 h time point, suggesting that the elevation of IRS-2 mRNA levels occurs prior to that of IRS-2 protein. To confirm that the progestin upregulation of IRS-2 was via transcriptional mechanisms, we preincubated MCF-7 cells with the transcription inhibitor 5,6-dichlorobenzimidazole riboside (DRB), and then stimulated the cells with R5020 in the continual presence of DRB. Not surprisingly, the IRS-2 mRNA upregulation by R5020 was suppressed by the DRB pretreatment (Figure 3a) . The result was also confirmed by RNA protection assay (data not shown). In line with this, immunoblotting showed that the IRS-2 protein increase by R5020 was also blocked by the DRB pretreatment (Figure 3b) , confirming that induction of IRS-2 mRNA synthesis is a prerequisite for the IRS-2 protein increase by progestins.
Furthermore, when hemagglutinin (HA) epitopetagged IRS-2 cDNA driven by the CMV promoter was either transiently or stably transfected into MCF-7 and other breast cancer cell lines, R5020 could not upregulate HA-IRS-2 levels in the transfected cells (data not shown), suggesting that the progesterone impact on IRS-2 expression in breast cancer cells does not occur via alteration of protein translation or stability, but rather relies on the original IRS-2 promoter context. In summary, these data suggest that the progesterone effect on IRS-2 in breast cancer cells is mediated by transcriptional mechanisms. Surprisingly, IRS-2 was not among the 94 progesterone-regulated genes identified in a recent study using T47D breast cancer cells and cDNA microarrays (Richer et al., 2002) . One explanation for the apparent discrepancy between this and our studies might be that IRS-2 mRNA is in low abundance in T47D cells and thus may not have been detected in the microarray analysis.
Since the IGFs utilize IRSs to transduce their signals in cells, we next examined how progestin's alteration of the IRS-2 levels might sensitize breast cancer cells to IGF signals. We preincubated MCF-7 cells with 10 À8 m R5020 for 24 h and then stimulated the cells with 100 ng/ ml IGF-I for 10 min. Immunoprecipitation with IRS-2 antibodies followed by immunoblotting demonstrated that R5020 pretreatment increased IRS-2 levels and consequently, the levels of tyrosine-phosphorylated IRS-2 induced by IGF-I. IRS-2 mobility was also shifted upward due to phosphorylation (Figure 4a ). R5020 by itself could not activate IRS-2. An important feature of the IRS-mediated response to IGF-I is docking of Grb-2 and the PI3K regulatory subunit p85, which leads to activation of the Ras/ERK and PI3K/Akt signaling pathways. As shown in Figure 4a , R5020 enhanced the IGF-I-triggered association of p85 and Grb-2 with tyrosine-phosphorylated IRS-2, most probably due to upregulation of activated IRS-2 levels, since total cellular p85 and Grb-2 levels were not changed by R5020 (Figure 4a ). In contrast, the association of p85 and Grb-2 to IRS-1 (not induced by progestins) after IGF-I stimulation was not enhanced by R5020. Moreover, upregulation of IRS-2 did not À8 m R5020, R5020 plus 10 À6 m RU486, or R5020 in the presence of the transcription inhibitor DRB (50 mm) after preincubation with DRB for 30 min. Total RNA was then isolated and 100 ng RNA was used in RT-PCR of IRS-1 and IRS-2, which was conducted using Superscript II reverse transcriptase (Invitrogen) and gene-specific primers (IRS-1:
. The PCR was performed at an annealing temperature of 601C and was subjected to 30 cycles. Products were revealed by ethidium bromide staining under UV after agarose gel electrophoresis. (b) MCF-7 cells were stimulated for 24 h with 10 À8 m R5020, R5020 plus 10 À6 m RU486, or R5020 in the presence of DRB after preincubation with DRB for 30 min. Cell lysate proteins were separated by 8% SDS-PAGE and immunoblotted with IRS-2 or IRS-1 antibodies impede the association of p85 and Grb-2 to IRS-1 upon IGF-I stimulation.
Since elevated IRS-2 levels were associated with increased p85 and Grb-2 binding, we measured subsequent Akt and ERK activation, using their phosphospecific antibodies. Immunoblot analysis revealed that activation of ERK and Akt triggered by IGF-I was higher after R5020 pretreatment, even though levels of total ERK and Akt were unaffected (Figure 4b ). Nor did R5020 by itself cause detectable phosphorylation of ERK and Akt. We consistently obtained similar results, that is, R5020 treatment led to 50-100% increase of IGF-I-stimulated phospho-Akt and phospho-ERK. It may be that we did not observe a more dramatic increase of Akt and ERK activation under the R5020 condition because the basal amount of IRS-1 is much higher than that of IRS-2, and IRS-1 is the predominant signaling molecule activated by IGF-I in MCF-7 as well as other ER þ breast cancer cells (Jackson et al., 1998) . Despite a considerable increase in expression after R5020 treatment, IRS-2 is still unable to fully overcome the dominant role of IRS-1 in IGF signal transduction.
It is also noted that estradiol seems to have a more prominent effect than progestins on enhancing IGF-Iinduced activation of ERK in MCF-7 cells (Lee et al., 1999; Dupont and Le Roith, 2001) , which is probably due to estrogen's induction of IRS-1 and IGF-IR, as well as IRS-2, whereas progesterone only induces IRS-2. Taken together, these data suggest that R5020 potentiates IGF-I signaling in breast cancer cells through upregulation of IRS-2. Given that IRS-2 has been shown to interact with and be activated by other pathways such as integrins (Shaw, 2001) , it is possible that progesterone also sensitizes breast cancer cells to IRS-2-mediated integrin signaling.
Previously, IRS-2 was identified as a progesterone response gene in PR-transfected HeLa cells, using differential display (Vassen et al., 1999) . So far, only a few PR-regulated genes have been characterized in breast cancer. This study represents the first attempt to characterize progesterone regulation of IRS signaling in breast cancer cells. Since IRSs are involved in effects of the IGFs, insulin, growth hormones, interleukins, and interferons, increased IRS-2 in cells may contribute to the promotion of cell proliferation, survival, and motility by these mitogens. Recently, the Women's Health Initiative, after a study of more than 16 000 women, concluded definitively that combined estrogen and progestin hormone therapy increases the risk of invasive breast cancer by 25% as compared to women taking placebo (Rossouw et al., 2002) . In another study (Schairer et al., 2000) , it was found that the risk of developing breast cancer was higher in women on estrogen and progestin therapy than in women who used estrogen therapy alone, which was confirmed by Ross et al. (2000) . These findings raised the question of why the addition of progestin to hormone replacement therapy would markedly enhance the risk of breast cancer relative to estrogen use alone. This enigma might be partly explained by the notion that progestins prime cells for extracellular signals through upregulation of pivotal cell signaling components. Our data presented here imply that progesterone may sensitize cells to signaling pathways that involve IRS-2 function. Future studies will be needed to determine the importance of the progesterone regulation of IRS-2 in breast cancer initiation and progression as well as normal mammary epithelial cell growth. À8 m R5020, and then stimulated with 100 ng/ml IGF-I for 10 min. Cell lysates (500 mg) were immunoprecipitated with IRS-2 antibodies at a 1:100 dilution. Aliquots of the immunoprecipitates were subjected to immunoblot analysis with the p85 (Upstate) and Grb-2 (Upstate) antibodies. Tyrosine phosphorylation of IRS-2 was detected with the specific phosphotyrosine antibody PY20 (Transduction Laboratories, Lexington, KY, USA). As a comparison, the association of p85 and Grb-2 with IRS-1 was also examined using immunoprecipitation with IRS-1 antibodies. (b) MCF-7 cells were first treated for 24 h with vehicle or 10 À8 m R5020, and then stimulated with 100 ng/ml IGF-I for 10 min. Cell lysates were separated by 8% SDS-PAGE and immunoblotted with antibodies against total Akt and ERK (Cell Signaling, Beverly, MA, USA) and their corresponding phosphorylation-specific antibodies (Akt: Ser 473; ERK: Thr202/Tyr204)
